Review Articles


Peterson EC, Gentry WB, Owens SM. Customizing monoclonal antibodies for the treatment of methamphetamine abuse: current and future applications. Adv Pharmacol. 2014; 69:107-27. PubMed PMID: 24484976.

Owens SM, Atchley WT, Hambuchen MD, Peterson EC, Gentry WB. Monoclonal antibodies as pharmacokinetic antagonists for the treatment of (+)-methamphetamine addiction. CNS Neurol Disord Drug Targets. 2011 Dec;10(8):892-8. PubMed PMID: 22229314.

Gentry WB, Rüedi-Bettschen D, Owens SM. Anti-(+)-methamphetamine monoclonal antibody antagonists designed to prevent the progression of human diseases of addiction. Clin Pharmacol Ther. 2010 Sep;88(3):390-3. PubMed PMID: 20668443.

Peterson EC, Owens SM. Designing immunotherapies to thwart drug abuse. Mol Interv. 2009 Jun;9(3):119-24. PubMed PMID: 19592672; PubMed Central PMCID: PMC2743871.

Gentry WB, Rüedi-Bettschen D, Owens SM. Development of active and passive human vaccines to treat methamphetamine addiction. Hum Vaccin. 2009 Apr;5(4):206-13. PubMed PMID: 19276653; PubMed Central PMCID: PMC2741685.

Peterson E, Owens SM, Henry RL. Monoclonal antibody form and function: manufacturing the right antibodies for treating drug abuse. AAPS J. 2006 May 26;8(2):E383-90. PubMed PMID: 16796389; PubMed Central PMCID: PMC3231570.

Owens SM. Antibodies as pharmacokinetic and metabolic modifiers of neurotoxicity. NIDA Res Monogr. 1997;173:259-72. PubMed PMID: 9260192.